Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 5, 2012, Pages 1369-1377

  Berk, Lori ^a   Mita, Monica M ^b   Kreisberg, Jeff ^b   Bedrosian, Camille L ^a,c   Tolcher, Anthony W ^b   Clackson, Tim ^a   Rivera, Victor M ^a  

^a ARIAD PHARMACEUTICALS INC   (United States)

^b CTRC Institute for Drug Development   (United States)

^c ALEXION PHARMACEUTICALS   (United States)

Author keywords

MTOR; Peripheral blood mononuclear cells (PBMCs); Pharmacodynamics; Ridaforolimus

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN S6; RIDAFOROLIMUS; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EIF4EBP1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; RAPAMYCIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MOUSE; MULTIPLE CYCLE TREATMENT; MYELOMA; NONHUMAN; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE; SKIN CELL; TUMOR CELL; ANIMAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; MONONUCLEAR CELL; MOUSE MUTANT; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; SKIN; TIME; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, SCID; NEOPLASMS; PHOSPHOPROTEINS; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6; SIROLIMUS; SKIN; TIME FACTORS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862272611     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1813-7     Document Type: Article

References (23)

1. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18:1926-1945 (Pubitemid 39071573)
2. Bjornsti M, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335-348 (Pubitemid 38579480)
3. Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F et al (2011) Ridaforolimus (AP23573, MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther 10:1059-1071
4. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, Sonenberg N (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15:2852-2864 (Pubitemid 33042055)
5. Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, Travis R, Sausville EA, Houghton PJ (2001) Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7:1758-1764 (Pubitemid 32708646)
6. Mothe-Satney I, Brunn GJ, McMahon LP, Capaldo CT, Abraham RT, Lawrence JC Jr (2000) Mammalian target of rapamycindependent phosphorylation of PHAS-I in four (S/T)P sites detected by phospho-specific antibodies. J Biol Chem 275:33836-33843
7. Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grunwald V, Weiss G, Hidalgo M (2003) Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887-2892 (Pubitemid 36993245)
8. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B et al (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64:252-261 (Pubitemid 38114106)
9. O'Donnell A, Faivre S, Burris HA III, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588-1595
10. Farag SS, Zhang S, Jansak BS, Wang X, Kraut E, Chan K, Dancey JE, Grever MR (2009) Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res 33:1475-1480
11. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L et al (2008) Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603-1610
12. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T et al (2008) Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26:361-367 (Pubitemid 351171685)
13. Squillace RM, Miller D, Cookson M, Wardwell SD, Moran L, Clapham D, Wang F, Clackson T, Rivera VM (2011) Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther 10:1959-1968
14. Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS (2005) Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 3:443-451 (Pubitemid 41232606)
15. Pal SK, Figlin RA (2010) Treatment options in metastatic renal cell carcinoma: focus on mTOR inhibitors. Clin Med Insights Oncol 4:43-53
16. Meric-Bernstam F, Gonzalez-Angulo AM (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27:2278-2287
17. Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Frigerio M, Lehmkuhl H, Marcen R, Morris R et al (2007) Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transpl Proc 39:2937-2950 (Pubitemid 350258649)
18. O'Reilly T, McSheehy PM (2010) Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 3:65-79
19. Sleijfer S, Wiemer E (2008) Dose selection in phase I studies: why we should always go for the top. J Clin Oncol 26:1576-1578
20. Mahalingam D, Sankhala K, Mita A, Giles FJ, Mita MM (2009) Targeting the mTOR pathway using deforolimus in cancer therapy. Future Oncol 5:291-303
21. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL et al (2009) A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 15:1428-1434
22. Sessa C, Tosi D, Vigano L, Albanell J, Hess D, Maur M, Cresta S, Locatelli A, Angst R, Rojo F et al (2010) Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol 21:1315-1322
23. Perotti A, Locatelli A, Sessa C, Hess D, Vigano L, Capri G, Maur M, Cerny T, Cresta S, Rojo F et al (2010) Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol 28:4554-4561